Abiopharma

🔍 Wells David R. (Director)

Company: HeartSciences Inc. (HSCS)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Acquired 15,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-12 | Code: A | equity_swap_involved: 0 | shares_owned_after: 15,000.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the "Plan") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below).
• F2: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date.
• F3: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof.